The Correlation between Malondialdehyde and Nerve Growth Factor Serum Level with Diabetic Peripheral Neuropathy Score
DOI:
https://doi.org/10.3889/oamjms.2019.029Keywords:
Malondialdehyde, Nerve growth factor, Diabetic peripheral neuropathy scoreAbstract
AIM: This study was conducted to identify malondialdehyde (MDA) serum level, nerve growth factor (NGF) serum level, diabetic peripheral neuropathy score and the correlation between MDA and NGF serum level with diabetic peripheral neuropathy score.
METHODS: A cross-sectional study was conducted to observe diabetic patients in the internal medicine department in Dr M. Djamil Hospital, Padang, Indonesia. The MDA serum level was measured using Beuge method with thiobarbituric acid. The NGF serum level was analysed using ELISA method. Diabetic peripheral neuropathy score was defined when history score in Michigan Neuropathy Screening Instrument (MNSI) ≥ 7 and physical assessment score in MNSI > 2.
RESULTS: Thirty subjects with diabetes has diabetic peripheral neuropathy score 3.53 (± 0.91), MDA serum level 2.16 (± 2.89) nmol/ml, and NGF serum level 10.56 (± 2.89) pg/dl. There were significant correlations between the MDA serum level and the diabetic peripheral neuropathy score (r = 0.364, p = 0.048), and between the NGF serum level with the diabetic peripheral neuropathy score (r = -0.59, p = 0.001).
CONCLUSION: There are high MDA serum level and low NGF serum level in patients with diabetic peripheral neuropathy. Low NGF serum level plays a bigger role than high MDA serum level in diabetic peripheral neuropathy.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018; 14(2):88-98. https://doi.org/10.1038/nrendo.2017.151 PMid:29219149 DOI: https://doi.org/10.1038/nrendo.2017.151
Ollendorf DA, Kotsanos JG, Wishner WJ, Friedman M, Cooper T, Bittoni M, et al. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care. 1998; 21:1240-5. https://doi.org/10.2337/diacare.21.8.1240 PMid:9702427 DOI: https://doi.org/10.2337/diacare.21.8.1240
Vincent AM, Russel JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev. 2004; 25(4):612-28. https://doi.org/10.1210/er.2003-0019 PMid:15294884 DOI: https://doi.org/10.1210/er.2003-0019
Park Y. Oxidative Stress and Diabetic Neuropathy. InDiabetes: Oxidative Stress and Dietary Antioxidants, 2014:3-13. DOI: https://doi.org/10.1016/B978-0-12-405885-9.00001-2
Donne ID, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarker of oxidative damage in human disease. Clin Chem. 2006; 52(4):601-23. https://doi.org/10.1373/clinchem.2005.061408 PMid:16484333 DOI: https://doi.org/10.1373/clinchem.2005.061408
Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001; 24:250–6. https://doi.org/10.2337/diacare.24.2.250 PMid:11213874 DOI: https://doi.org/10.2337/diacare.24.2.250
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994; 17:1281– 9. https://doi.org/10.2337/diacare.17.11.1281 PMid:7821168 DOI: https://doi.org/10.2337/diacare.17.11.1281
Subekti I. Neuropati perifer. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Buku ajar ilmu penyakit dalam. 5th eds. Jakarta: Pusat Penelitian Ilmu Penyakit Dalam FKUI, 2010:1947-51.
Tesfaye S. Neuropathy in diabetes. Medicine. 2010; 38(12):649-55. https://doi.org/10.1016/j.mpmed.2010.08.012 DOI: https://doi.org/10.1016/j.mpmed.2010.08.012
Pittenger G, Vinik A. Nerve growth factor and diabetic neuropathy. Exp Diabesity Res. 2003; 4(4):271-85. https://doi.org/10.1155/EDR.2003.271 PMid:14668049 PMCid:PMC2478610 DOI: https://doi.org/10.1155/EDR.2003.271
Yasuda H, Terada M, Maeda K, Kogawa S, Sanada M, Haneda M, et al. Diabetic neuropathy and nerve regeneration. Prog Neurobiol. 2003; 69(4):229-85. https://doi.org/10.1016/S0301-0082(03)00034-0 DOI: https://doi.org/10.1016/S0301-0082(03)00034-0
Maitreyess DS. Study of free iron, superoxide dismutase, malondialdehyde and glycated hemoglobin in type 2 diabetes mellitus with and without microvascular complications (dissertation). Bangalore: Rajiv Gandhi University of Health Sciences, 2011.
Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes- associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med. 2003; 34(12):1563. https://doi.org/10.1016/S0891-5849(03)00185-0 DOI: https://doi.org/10.1016/S0891-5849(03)00185-0
Bhutia Y, Ghosh A, Sherpa ML, Pal R, Mohanta PK. Serum malondialdehyde level: surrogate stress marker in the Sikkimese diabetics. J Nat Sci Biol Med. 2011; 2(1):107-12. https://doi.org/10.4103/0976-9668.82309 PMid:22470243 PMCid:PMC3312689 DOI: https://doi.org/10.4103/0976-9668.82309
Jalees SS, Rosaline M. Study of malondialdehyde and estimation of blood glucose levels in patients with diabetes mellitus with cataract. International Journal of Clinical Biochemistry and Research. 2017; 4(3):319-23.
Zavar-Reza J, Shahmoradi H, Mohammadyari A, Mohammadbeigi M, Hosseini R, Vakili M, et al. Evaluation of malondialdehyde in type 2 diabetic patients with coronary artery disease. J Biol Today's World. 2014; 3(6):129-32. https://doi.org/10.15412/J.JBTW.01030602 DOI: https://doi.org/10.15412/J.JBTW.01030602
Mahmoud ME, Doria AEF, Heba AS, Fawzy AEM, Nashwa MA. Assessment of nerve growth factor and nerve conduction velocity in diabetic patients with neuropathy. Egypt J Neurol Psychiatr Neurosurg. 2009; 46(1):101-9.
Obrosova IG, Fathallah L, Stevens MJ. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol. 2001; 172:211–9. https://doi.org/10.1006/exnr.2001.7789 PMid:11681853 DOI: https://doi.org/10.1006/exnr.2001.7789
Tosaki T, Kamiya H, Yasuda Y, Naruse K, Kato K, Kozakae M, et al. Reduced NGF secretion by Schwann cells under the high glucose condition decreases neurite outgrowth of DRG neurons. Exp Neurol. 2008; 213:381–7. https://doi.org/10.1016/j.expneurol.2008.06.017 PMid:18675804 DOI: https://doi.org/10.1016/j.expneurol.2008.06.017
Yilmaz M, Aktug H, Oltulu F, Erbas O. Neuroprotective effects of folic acid on experimental diabetic peripheral neuropathy. Toxicology Industrial Health. 2013:1-10. DOI: https://doi.org/10.1177/0748233713511513
Harsono. Neuropati diabetika. In: Buku ajar neurologi klinis. Yogyakarta: Perhimpunan Dokter Spesialis Syaraf Indonesia - Gadjah Mada University Press, 2005.
Aziza SAH, El-Haggar M, Abo-Zaid OA, Hassanien MR, El-Shawarby R. Biomarkers of oxidative stress of sciatic nerve tissues in experimental diabetic neuropathy. Journal of Medical Sciences. 2014; 14(1):12-20. https://doi.org/10.3923/jms.2014.12.20 DOI: https://doi.org/10.3923/jms.2014.12.20
Martinez-Hervaz S, Mendez MM, Folgado J, Tormos C, Ascaso P, Peiro M, et al. Altered Semmes-Weinstein monofilament test results are associated with oxidative stress markers in type 2 diabetic subjects. J Transl Med. 2017; 15:187-94. https://doi.org/10.1186/s12967-017-1291-8 PMid:28874161 PMCid:PMC5586059 DOI: https://doi.org/10.1186/s12967-017-1291-8
Li R, Ma J, Wu Y, Nangle M, Zou S, Li Y, et al. Dual delivery of NGF and bFGF coacervater ameliorates diabetic peripheral neuropathy via inhibiting Schwann cells apoptosis. Int J Biol Sci. 2017; 13:640-51. https://doi.org/10.7150/ijbs.18636 PMid:28539836 PMCid:PMC5441180 DOI: https://doi.org/10.7150/ijbs.18636
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Eva Decroli, Asman Manaf, Syafril Syahbuddin, Yuliarni Syafrita, Dwisari Dillasamola
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
